{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:47:54Z","timestamp":1794282474790,"version":"4.9.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020487","name":"Break Through Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005979","name":"Lustgarten Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA117969"],"award-info":[{"award-number":["P01 CA117969"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA274371"],"award-info":[{"award-number":["U54CA274371"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA16672"],"award-info":[{"award-number":["P30CA16672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ergon Foundation"},{"name":"Mullick Foundation"},{"name":"Shelby Lavine Scholar"},{"DOI":"10.13039\/100001315","name":"Sid W. Richardson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutations in\n                    <jats:italic>KRAS<\/jats:italic>\n                    are a dominant driver of pancreatic ductal adenocarcinoma (PDAC), with about 50% of patients presenting with\n                    <jats:italic>KRAS<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>G12D<\/jats:italic>\n                    <\/jats:sup>\n                    mutations. Small molecule inhibitors targeting KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    suppress PDAC; however, the contribution of the tumor microenvironment (TME) to the sustained efficacy of KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    inhibition and mechanisms of resistance to KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    suppression remain to be elucidated. Here, integrated spatial transcriptomics, single-cell RNA sequencing, and CODEX-based spatial proteomics analyses of PDAC mouse models uncover that while KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    inhibition by MRTX1133 initially increases CD11c\n                    <jats:sup>+<\/jats:sup>\n                    cells and T cell infiltration proximal to cancer cells, long-term treatment results in reversal of the immune responses leading to resistance promoted by multiprotein mediator complex associated kinase CDK8. CDK8 imparts this resistance via induction of CXCL2 chemokine secretion, inhibition of FAS expression, and remodeling of the TME to promote immune evasion. Targeting CDK8 by itself or in combination with \u03b1CTLA-4 immunotherapy overcomes resistance to KRAS\n                    <jats:sup>G12D<\/jats:sup>\n                    inhibition. We also provide evidence of CDK8 upregulation in PDX tumors resistant to inhibitors selective for RAS(ON) and RAS\n                    <jats:sup>G12D<\/jats:sup>\n                    (ON): daraxonrasib and zoldonrasib, respectively, highlighting a common KRAS vulnerability node for TME resistance.\n                  <\/jats:p>","DOI":"10.1038\/s44318-026-00854-5","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:52:54Z","timestamp":1783774374000},"page":"5727-5758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4092-4991","authenticated-orcid":false,"given":"Kathleen M","family":"McAndrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnan K","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs M","family":"Comptdaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amari M","family":"Sockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami J","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patience J","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah I","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L","family":"Kirtley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara A","family":"Moreno Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyu","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0511-1888","authenticated-orcid":false,"given":"David H","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Khazaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aislyn","family":"Schalck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron A","family":"Bickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Kavitha","family":"Sthanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan R","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyasee V","family":"Kumbhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent A","family":"Arian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Barekatain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Paradiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola A","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Sobhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alondra N","family":"Camacho-Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara E","family":"Bornes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Thao","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-547X","authenticated-orcid":false,"given":"Raghu","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"854_CR1","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1101\/gad.1158703","volume":"17","author":"AJ Aguirre","year":"2003","unstructured":"Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA (2003) Activated Kras and Ink4a\/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112\u20133126","journal-title":"Genes Dev"},{"key":"854_CR2","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y et al (2020) EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov 10:1129\u20131139","journal-title":"Cancer Discov"},{"key":"854_CR3","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ et al (2021) Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med 384:2382\u20132393","journal-title":"N Engl J Med"},{"key":"854_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878","journal-title":"Sci Rep"},{"key":"854_CR5","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A et al (2023) Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol 41:4097\u20134106","journal-title":"J Clin Oncol"},{"key":"854_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41587-021-00830-w","volume":"40","author":"DM Cable","year":"2022","unstructured":"Cable DM, Murray E, Zou LS, Goeva A, Macosko EZ, Chen F, Irizarry RA (2022) Robust decomposition of cell type mixtures in spatial transcriptomics. Nat Biotechnol 40:517\u2013526","journal-title":"Nat Biotechnol"},{"key":"854_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.celrep.2016.05.063","volume":"16","author":"A Carugo","year":"2016","unstructured":"Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF et al (2016) In vivo functional platform targeting patient-derived xenografts identifies WDR5-Myc association as a critical determinant of pancreatic cancer. Cell Rep 16:133\u2013147","journal-title":"Cell Rep"},{"key":"854_CR8","doi-asserted-by":"publisher","first-page":"10208","DOI":"10.1073\/pnas.1710467114","volume":"114","author":"M Chen","year":"2017","unstructured":"Chen M, Liang J, Ji H, Yang Z, Altilia S, Hu B, Schronce A, McDermott MSJ, Schools GP, Lim CU et al (2017) CDK8\/19 Mediator kinases potentiate induction of transcription by NFkappaB. Proc Natl Acad Sci USA 114:10208\u201310213","journal-title":"Proc Natl Acad Sci USA"},{"key":"854_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI59227","volume":"122","author":"MA Collins","year":"2012","unstructured":"Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca di Magliano M (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122:639\u2013653","journal-title":"J Clin Invest"},{"key":"854_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27349-7","volume":"12","author":"Y Deng","year":"2021","unstructured":"Deng Y, Xia X, Zhao Y, Zhao Z, Martinez C, Yin W, Yao J, Hang Q, Wu W, Zhang J et al (2021) Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun 12:7041","journal-title":"Nat Commun"},{"key":"854_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","volume":"10","author":"P Dey","year":"2020","unstructured":"Dey P, Li J, Zhang J, Chaurasiya S, Strom A, Wang H, Liao WT, Cavallaro F, Denz P, Bernard V et al (2020) Oncogenic KRAS-driven metabolic reprogramming in pancreatic cancer cells utilizes cytokines from the tumor microenvironment. Cancer Discov 10:608\u2013625","journal-title":"Cancer Discov"},{"key":"854_CR12","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, Hennessey CJ, Jordan AC, Morgado M, Dasgupta S et al (2024) Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov 14:2135\u20132161","journal-title":"Cancer Discov"},{"key":"854_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nsmb.1752","volume":"17","author":"AJ Donner","year":"2010","unstructured":"Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM (2010) CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat Struct Mol Biol 17:194\u2013201","journal-title":"Nat Struct Mol Biol"},{"key":"854_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/09553000902838566","volume":"85","author":"EV Efimova","year":"2009","unstructured":"Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V, Lokshin A, Roizman B, Weichselbaum RR, Khodarev NN (2009) Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 85:421\u2013431","journal-title":"Int J Radiat Biol"},{"key":"854_CR15","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41388-023-02676-9","volume":"42","author":"J Feng","year":"2023","unstructured":"Feng J, Hu Z, Xia X, Liu X, Lian Z, Wang H, Wang L, Wang C, Zhang X, Pang X (2023) Feedback activation of EGFR\/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer. Oncogene 42:1620\u20131633","journal-title":"Oncogene"},{"key":"854_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature07179","volume":"455","author":"R Firestein","year":"2008","unstructured":"Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S et al (2008) CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455:547\u2013551","journal-title":"Nature"},{"key":"854_CR17","doi-asserted-by":"publisher","first-page":"ra77","DOI":"10.1126\/scisignal.aaa5823","volume":"8","author":"K Foley","year":"2015","unstructured":"Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, Kleponis J, Wu AA, Sharma R, Jiang Q et al (2015) Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Sci Signal 8:ra77","journal-title":"Sci Signal"},{"key":"854_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162\u2013174","journal-title":"Nat Rev Immunol"},{"key":"854_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, Drizyte-Miller K, Papke B, Yang R, Amparo AM et al (2023) Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res 83:141\u2013157","journal-title":"Cancer Res"},{"key":"854_CR20","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","volume":"83","author":"KCM Gulay","year":"2023","unstructured":"Gulay KCM, Zhang X, Pantazopoulou V, Patel J, Esparza E, Pran Babu DS, Ogawa S, Weitz J, Ng I, Mose ES et al (2023) Dual inhibition of KRASG12D and Pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res 83:3001\u20133012","journal-title":"Cancer Res"},{"key":"854_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s43018-022-00500-z","volume":"4","author":"P Gulhati","year":"2023","unstructured":"Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, Ruiz SH, Soto LS, Parra E, Ying H et al (2023) Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer 4:62\u201380","journal-title":"Nat Cancer"},{"key":"854_CR22","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E et al (2022) Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med 28:2171\u20132182","journal-title":"Nat Med"},{"key":"854_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA et al (2020) The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov 10:54\u201371","journal-title":"Cancer Discov"},{"key":"854_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1535-6108(03)00309-X","volume":"4","author":"SR Hingorani","year":"2003","unstructured":"Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437\u2013450","journal-title":"Cancer Cell"},{"key":"854_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469\u2013483","journal-title":"Cancer Cell"},{"key":"854_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714\u2013726","journal-title":"Nat Rev Cancer"},{"key":"854_CR27","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1158\/2159-8290.CD-19-0597","volume":"10","author":"P Hou","year":"2020","unstructured":"Hou P, Kapoor A, Zhang Q, Li J, Wu CJ, Li J, Lan Z, Tang M, Ma X, Ackroyd JJ et al (2020) Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer. Cancer Discov 10:1058\u20131077","journal-title":"Cancer Discov"},{"key":"854_CR28","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","volume":"13","author":"JC Hunter","year":"2015","unstructured":"Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD (2015) Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res 13:1325\u20131335","journal-title":"Mol Cancer Res"},{"key":"854_CR29","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L et al (2018) Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell 172:578\u2013589 e517","journal-title":"Cell"},{"key":"854_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B et al (2014) Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158:185\u2013197","journal-title":"Cell"},{"key":"854_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccr.2013.10.009","volume":"24","author":"H Katoh","year":"2013","unstructured":"Katoh H, Wang D, Daikoku T, Sun H, Dey SK, Dubois RN (2013) CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 24:631\u2013644","journal-title":"Cancer Cell"},{"key":"854_CR32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, Shoush J, Quinones L, Brown NV, Bassett JB et al (2023) Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov 13:298\u2013311","journal-title":"Cancer Discov"},{"key":"854_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41587-021-01139-4","volume":"40","author":"V Kleshchevnikov","year":"2022","unstructured":"Kleshchevnikov V, Shmatko A, Dann E, Aivazidis A, King HW, Li T, Elmentaite R, Lomakin A, Kedlian V, Gayoso A et al (2022) Cell2location maps fine-grained cell types in spatial transcriptomics. Nat Biotechnol 40:661\u2013671","journal-title":"Nat Biotechnol"},{"key":"854_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","volume":"63","author":"BA Lanman","year":"2020","unstructured":"Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK, Chen JJ, Chen N, Frohn MJ, Goodman G et al (2020) Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. J Med Chem 63:52\u201365","journal-title":"J Med Chem"},{"key":"854_CR35","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.celrep.2016.11.062","volume":"17","author":"CR Lee","year":"2016","unstructured":"Lee CR, Kwak Y, Yang T, Han JH, Park SH, Ye MB, Lee W, Sim KY, Kang JA, Kim YC et al (2016) Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-beta during murine colitis. Cell Rep 17:3219\u20133232","journal-title":"Cell Rep"},{"key":"854_CR36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.aad6204","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito P, Solomon M, Li LS, Hansen R, Rosen N (2016) Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351:604\u2013608","journal-title":"Science"},{"key":"854_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, Han J, Hsu WH, LaBella KA, Deng P, Shang X, Tallon de Lara P, Cai L, Jiang S, DePinho RA (2025) Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model. Cancer Discov 15:162\u2013178","journal-title":"Cancer Discov"},{"key":"854_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn4180","volume":"381","author":"X Lv","year":"2023","unstructured":"Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E et al (2023) Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science 381:eabn4180","journal-title":"Science"},{"key":"854_CR39","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.devcel.2023.07.025","volume":"58","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, LeBleu VS, Ramirez EV, Chen Y, Li B, Sockwell AM, Gagea M, Sugimoto H, Sthanam LK, Tampe D et al (2023a) Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8(+) T cells. Dev Cell 58:1562\u20131577.e1568","journal-title":"Dev Cell"},{"key":"854_CR40","doi-asserted-by":"crossref","unstructured":"Mahadevan KK, Maldonado AS, Li B, Bickert AA, Kapercyzk-Perdyan A, Kumbhar SV, Piya S, Sockwell A, Morse SJ, Arian K et al (2025) Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2025.02.28.640711v2","DOI":"10.1101\/2025.02.28.640711"},{"key":"854_CR41","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, Sockwell AM, Kirtley ML, Morse SJ, Moreno Diaz BA et al (2023b) KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell 41:1606\u20131620.e1608","journal-title":"Cancer Cell"},{"key":"854_CR42","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S0167-5699(99)01469-3","volume":"20","author":"A Mantovani","year":"1999","unstructured":"Mantovani A (1999) The chemokine system: redundancy for robust outputs. Immunol Today 20:254\u2013257","journal-title":"Immunol Today"},{"key":"854_CR43","doi-asserted-by":"crossref","unstructured":"Martin M (2011) Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J 17:10\u201312","DOI":"10.14806\/ej.17.1.200"},{"key":"854_CR44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267\u2013273","journal-title":"Nat Genet"},{"key":"854_CR45","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T et al (2016) Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov 6:316\u2013329","journal-title":"Cancer Discov"},{"key":"854_CR46","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"BJ Raphael","year":"2017","unstructured":"Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, Robertson AG, Cherniack AD, Gupta M, Getz G et al (2017) Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32:185\u2013203.e113","journal-title":"Cancer Cell"},{"key":"854_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, Kanikarla P, Gao F, Zhang Y, Zhou L et al (2022) KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy. Cell Rep 39:110993","journal-title":"Cell Rep"},{"key":"854_CR48","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J et al (2005) Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:6477\u20136489","journal-title":"J Immunol"},{"key":"854_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-213X-1-4","volume":"1","author":"S Srinivas","year":"2001","unstructured":"Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, Costantini F (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1:4","journal-title":"BMC Dev Biol"},{"key":"854_CR50","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z et al (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29:832\u2013845","journal-title":"Cancer Cell"},{"key":"854_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS et al (2023) Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med 388:33\u201343","journal-title":"N Engl J Med"},{"key":"854_CR52","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545\u201315550","journal-title":"Proc Natl Acad Sci USA"},{"key":"854_CR53","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich E, Shain AH, Botton T, Bastian BC (2016) CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol 12:e1004873","journal-title":"PLoS Comput Biol"},{"key":"854_CR54","unstructured":"Van der Auwera GA, O\u2019Connor BD (2020) Genomics in the cloud: using Docker, GATK, and WDL in Terra, 1st edition. O\u2019Reilly Media"},{"key":"854_CR55","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.cell.2018.05.061","volume":"174","author":"D van Dijk","year":"2018","unstructured":"van Dijk D, Sharma R, Nainys J, Yim K, Kathail P, Carr AJ, Burdziak C, Moon KR, Chaffer CL, Pattabiraman D et al (2018) Recovering gene interactions from single-cell data using data diffusion. Cell 174:716\u2013729.e727","journal-title":"Cell"},{"key":"854_CR56","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ccell.2018.10.001","volume":"34","author":"AV Vaseva","year":"2018","unstructured":"Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH et al (2018) KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism. Cancer Cell 34:807\u2013822.e807","journal-title":"Cancer Cell"},{"key":"854_CR57","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jcmgh.2022.02.016","volume":"13","author":"A Velez-Delgado","year":"2022","unstructured":"Velez-Delgado A, Donahue KL, Brown KL, Du W, Irizarry-Negron V, Menjivar RE, Lasse Opsahl EL, Steele NG, The S, Lazarus J et al (2022) Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming. Cell Mol Gastroenterol Hepatol 13:1673\u20131699","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"854_CR58","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nature13611","volume":"514","author":"A Viale","year":"2014","unstructured":"Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V et al (2014) Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514:628\u2013632","journal-title":"Nature"},{"key":"854_CR59","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, Lee B, Orlen M, Tian S, Stalnecker CA et al (2024) Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629:927\u2013936","journal-title":"Nature"},{"key":"854_CR60","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL et al (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149:656\u2013670","journal-title":"Cell"},{"key":"854_CR61","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1158\/2159-8290.CD-20-0442","volume":"10","author":"MP Zafra","year":"2020","unstructured":"Zafra MP, Parsons MJ, Kim J, Alonso-Curbelo D, Goswami S, Schatoff EM, Han T, Katti A, Fernandez MTC, Wilkinson JE et al (2020) An in vivo Kras allelic series reveals distinct phenotypes of common oncogenic variants. Cancer Discov 10:1654\u20131671","journal-title":"Cancer Discov"},{"key":"854_CR62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","volume":"66","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, Rhim AD, Simeone DM, Beatty GL, Pasca di Magliano M (2017) Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut 66:124\u2013136","journal-title":"Gut"},{"key":"854_CR63","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF, Saiki AY, Mohn D, Achanta P et al (2021) Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature 599:679\u2013683","journal-title":"Nature"},{"key":"854_CR64","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature16064","volume":"527","author":"X Zheng","year":"2015","unstructured":"Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527:525\u2013530","journal-title":"Nature"}],"container-title":["The EMBO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44318-026-00854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44318-026-00854-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44318-026-00854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:31:53Z","timestamp":1786948313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44318-026-00854-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":64,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8,17]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1038\/s44318-026-00854-5","relation":{},"ISSN":["1460-2075"],"issn-type":[{"value":"1460-2075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AM is listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection. TP Heffernan receives advisory fees from Cullgen Inc., Psivant Therapeutics, and Isomorphic Labs. The remaining authors declare no relevant\u00a0competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}